Fecha de actualización: marzo de 2021   

 

Discovery
Click for more info Project Teaser


Indication
Target
CM-272 Cancer
Research Group
DNMT & G9a

 

CM-1315 Onco-immunology

Research Group

Disruption of FOXP3 dimerization

 

Apo-Insulin

Diabetes

Research Group

Insulin
Receptor

 

Sushi-IL15-
Apo
Onco-immunology
Research Group
Receptor
IL-15

 

Apo-
FGF19
Liver
regeneration
Research Group
FGF19 receptor

 

Target ID In vitro
Assays
Hit ID In vivo PoC
/ Lead id
ADMET / PK
Optimización
Preclinical Clinical
 
   
     
     
     
IP


ok
ok
ok
ok
ok
 


 

Early Discovery
Click for more info Project Teaser


Indication
Target
Viro Therapy Onco-immunology
Research Group

Inmune response

 

Eliratra Onco-immunology

Research Group

Immune response

 

CM-1351 Onco-immunologyResearch Group

Disruption Foxp3/ NFAT interaction

 

CM-3132 Dravet Syndrome
Research Group
SCN1A

 

Target ID In vitro
Assays
Hit ID In vivo PoC
/ Lead id
ADMET / PK
Optimización
 
 
 
Partners
IP

   
   
Undisclosed in-process
  in-process
 


 

Licensed Products in PreClinical & Clinical Phases
Click for more info Project Teaser


Indication
CardioPatch Heart Failure

Research Group

EDA vaccine Cervical
Cancer

Research Group

CM-1349 Acute
intermittent porphyria

Research Group

a5-IFN Manufacturing
rh-CT 1 * Acute kidney injure
AAV-PBGD * Acute intermittent Porphyria
CM-144 * Scleroderma
AAV-GBA GT for CNS
C4 activation fragment Lung Cancer

Research Group

R&D Preclinical
Phase I Phase II Phase III
     
     
     
 
 
 
 
     
     
Licensed
IP


Viscofan ok
Formune ok
Moderna Therapeutics ok
BioTechpharma ok
Bita ok
Uniqure ok
Bita ok
Handl therapeutics ok
Amadix ok

 

* Terminated